MARKET

IKT

IKT

Inhibikase Therapeutics Inc
NASDAQ
1.500
-0.010
-0.66%
After Hours: 1.500 0 0.00% 17:01 12/05 EST
OPEN
1.540
PREV CLOSE
1.510
HIGH
1.570
LOW
1.485
VOLUME
101.32K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
1.330
MARKET CAP
181.35M
P/E (TTM)
-1.3065
1D
5D
1M
3M
1Y
5Y
1D
Inhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
TipRanks · 4d ago
Weekly Report: what happened at IKT last week (1124-1128)?
Weekly Report · 4d ago
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
TipRanks · 11/25 03:52
Major Shareholder Makes a Big Move on Inhibikase Therapeutics Stock!
TipRanks · 11/25 02:08
Sands Capital Life Sciences Pulse Fund II Reports Acquisition of Inhibikase Therapeutics Common Shares
Reuters · 11/24 20:47
Weekly Report: what happened at IKT last week (1117-1121)?
Weekly Report · 11/24 09:12
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
TipRanks · 11/21 21:48
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/21 12:05
More
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Webull offers Inhibikase Therapeutics Inc stock information, including NASDAQ: IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.